Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Raskin

Showing results (101-110 of 125) with videos related to

Pageof 13
Sort By:
The American Journal of Medicine|July 3, 2007
Body weight changes with beta-blocker use: results from GEMINIFranz H Messerli, David S H Bell, Vivian Fonseca, et al.
Journal of Diabetes and Its Complications|October 16, 2018
Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney diseaseGlenn M Chertow, Gerald B Appel, Geoffrey A Block, et al.
Diabetes Technology & Therapeutics|September 29, 2022
A Multicenter Randomized Trial Evaluating the Insulin-Only Configuration of the Bionic Pancreas in Adults with Type 1 DiabetesDavida Kruger, Alex Kass, Jacqueline Lonier, et al.
Diabetes Care|September 13, 2013
B-lymphocyte depletion with rituximab and β-cell function: two-year resultsMark D Pescovitz, Carla J Greenbaum, Brian Bundy, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 14, 2024
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks TreatmentElena A Christofides, Andrzej Stankiewicz, Douglas Denham, et al.
Plos One|November 15, 2024
Glycemia reduction in type 2 diabetes-Hypoglycemia outcomes: A randomized clinical trialElizabeth R Seaquist, Lawrence S Phillips, Alokananda Ghosh, et al.
The New England Journal of Medicine|November 27, 2009
Rituximab, B-lymphocyte depletion, and preservation of beta-cell functionMark D Pescovitz, Carla J Greenbaum, Heidi Krause-Steinrauf, et al.
Diabetes Care|December 4, 2013
Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatmentTihamer Orban, Brian Bundy, Dorothy J Becker, et al.
Lancet (London, England)|July 2, 2011
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trialTihamer Orban, Brian Bundy, Dorothy J Becker, et al.
The Lancet. Diabetes & Endocrinology|July 2, 2021
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen E Gitelman, Brian N Bundy, Ele Ferrannini, et al.
Pageof 13

Showing results (101-110 of 125) with videos related to

Sort By:
Pageof 13
The American Journal of Medicine|July 3, 2007
Body weight changes with beta-blocker use: results from GEMINIFranz H Messerli, David S H Bell, Vivian Fonseca, et al.
Journal of Diabetes and Its Complications|October 16, 2018
Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney diseaseGlenn M Chertow, Gerald B Appel, Geoffrey A Block, et al.
Diabetes Technology & Therapeutics|September 29, 2022
A Multicenter Randomized Trial Evaluating the Insulin-Only Configuration of the Bionic Pancreas in Adults with Type 1 DiabetesDavida Kruger, Alex Kass, Jacqueline Lonier, et al.
Diabetes Care|September 13, 2013
B-lymphocyte depletion with rituximab and β-cell function: two-year resultsMark D Pescovitz, Carla J Greenbaum, Brian Bundy, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 14, 2024
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks TreatmentElena A Christofides, Andrzej Stankiewicz, Douglas Denham, et al.
Plos One|November 15, 2024
Glycemia reduction in type 2 diabetes-Hypoglycemia outcomes: A randomized clinical trialElizabeth R Seaquist, Lawrence S Phillips, Alokananda Ghosh, et al.
The New England Journal of Medicine|November 27, 2009
Rituximab, B-lymphocyte depletion, and preservation of beta-cell functionMark D Pescovitz, Carla J Greenbaum, Heidi Krause-Steinrauf, et al.
Diabetes Care|December 4, 2013
Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatmentTihamer Orban, Brian Bundy, Dorothy J Becker, et al.
Lancet (London, England)|July 2, 2011
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trialTihamer Orban, Brian Bundy, Dorothy J Becker, et al.
The Lancet. Diabetes & Endocrinology|July 2, 2021
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen E Gitelman, Brian N Bundy, Ele Ferrannini, et al.
Pageof 13